19.3 C
New York
Tuesday, May 30, 2023

Sangamo Therapeutics Inc. (NASDAQ: SGMO) stock fall in the current market session. Here’s what’s happening?

Sangamo Therapeutics Inc. (NASDAQ: SGMO) stock declined by 1.01% at last close while the SGMO stock price continues to fall in the current-market at last check. There is no recent news available regarding this downfall in SGMO share price, as of now. Sangamo Therapeutics is dedicated to developing genomic therapies that have the ability to change patients’ lives through gene therapy, cell therapy, and genome engineering.

Upcoming Events

Sangamo Therapeutics, a genomic medicine firm, recently announced that its first quarter financial results for 2021 will be released after the market closes on Tuesday, May 4, 2021.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


On April 28, 2021

SGMO reported its upcoming data demonstrations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which will be held May 11-14, 2021, in an online format.

Jason Fontenot, Ph.D., Chief Scientific Officer at Sangamo commented:

SGMO’s zinc finger technology has portrayed its flexibility in a wide variety of clinical fields, and the upcoming presentations at ASGCT will concentrate on one field where there is an especially strong unmet need: neurodegenerative diseases. The capacity for zinc finger protein transcription factors to modify the expression of targeted genes in ALS and Parkinson’s disease is shown in these abstracts. SGMO is inspired by these preliminary findings, which show the accuracy, efficacy, and promise of their transcriptional control technology as a potentially transformative genomic medicine solution for these difficult-to-treat diseases. SGMO is excited to continue their studies.

The presentations involve,

On Tuesday May 11, the presentation will be about “Selective repression of C9ORF72 repeat expansion-containing sense and antisense transcripts for the cure of amyotrophic lateral sclerosis”and “Alpha-synuclein repression by the use of zinc finger protein transcription factors which is a novel therapeutic approach for the cure of Parkinson’s disease”.

Latest news

Related news


Please enter your comment!
Please enter your name here